Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.

Nanomedicine (London, England) Pub Date : 2024-08-08 DOI:10.1080/17435889.2024.2382668

Pavan K Yadav, Saurabh Verma, Divya Chauhan, Pooja Yadav, Amrendra K Tiwari, Ravi Saklani, Deepak Gupta, Rafquat Rana, Aarti Abhishek Shah, Sonia Verma, Kothuri Naresh, Jiaur R Gayen, Manish K Chourasia

{"title":"Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.","authors":"Pavan K Yadav, Saurabh Verma, Divya Chauhan, Pooja Yadav, Amrendra K Tiwari, Ravi Saklani, Deepak Gupta, Rafquat Rana, Aarti Abhishek Shah, Sonia Verma, Kothuri Naresh, Jiaur R Gayen, Manish K Chourasia","doi":"10.1080/17435889.2024.2382668","DOIUrl":null,"url":null,"abstract":"Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines. Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher Cmax for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ). Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2382668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines. Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher C_max for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ). Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通过 LC-MS/MS 同时估算紫杉醇和硼替佐米：制药和药代动力学应用。

目的与目标：本研究评估了紫杉醇（PTX）和硼替佐米（BTZ）联合治疗乳腺癌的潜力。材料与方法：通过盒-贝肯设计（BBD）对纳米制剂进行了优化，并按照美国食品药品管理局的指南进行了方法验证。结果：PTX、BTZ和内标物的多反应监测跃迁分别为m/z 855.80→286.60、366.80→226.00和179.80→110.00。采用 C18 Luna 色谱柱，以 0.1% FA in MeOH:10 mM 乙酸铵溶液洗脱。纳米制剂的尺寸为 133.9 ± 1.97 nm，PDI 为 0.19 ± 0.01，zeta 电位为 -19.20 ± 1.36 mV。药代动力学显示，PTX-BTZ-NE 的 Cmax（313.75 ± 10.71 ng/ml PTX，11.92 ± 0.53 ng/ml BTZ）高于游离 PTX-BTZ（104 ± 13.06 ng/ml PTX，1.9 ± 0.08 ng/ml BTZ）。结论未来的研究结果将有助于使用 PTX 和 BTZ 治疗乳腺癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量